Multimodal imaging findings in patients with glioblastoma with extensive coagulative necrosis related to regorafenib.
作者信息
Werner Jan-Michael, Wollring Michael M, Tscherpel Caroline, Rosen Elena K, Werr Lisa, Stetter Isabelle, Rueß Daniel, Ruge Maximilian I, Brunn Anna, Al Shughri Abdulkader, Kabbasch Christoph, Fink Gereon R, Langen Karl-Josef, Galldiks Norbert
机构信息
Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany.
出版信息
Neuro Oncol. 2023 Jun 2;25(6):1193-1195. doi: 10.1093/neuonc/noad051.
Abstract
摘要
相似文献
1
Multimodal imaging findings in patients with glioblastoma with extensive coagulative necrosis related to regorafenib.胶质母细胞瘤患者中与瑞戈非尼相关的广泛凝固性坏死的多模态成像结果。
Neuro Oncol. 2023 Jun 2;25(6):1193-1195. doi: 10.1093/neuonc/noad051.
2
PET/MR in recurrent glioblastoma patients treated with regorafenib: [F]FET and DWI-ADC for response assessment and survival prediction.替莫唑胺联合放疗同步与序贯卡培他滨治疗新诊断胶质母细胞瘤的多中心随机对照 III 期临床研究
Br J Radiol. 2022 Jan 1;95(1129):20211018. doi: 10.1259/bjr.20211018. Epub 2021 Nov 23.
3
Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI.使用多参数动态 18F-氟乙基酪氨酸 PET-MRI 诊断脑胶质瘤复发。
Eur J Radiol. 2018 Jun;103:32-37. doi: 10.1016/j.ejrad.2018.04.003. Epub 2018 Apr 4.
4
Potential for differentiation of glioma recurrence from radionecrosis using integrated F-fluoroethyl-L-tyrosine (FET) positron emission tomography/magnetic resonance imaging: A prospective evaluation.采用 F-氟代乙基-L-酪氨酸（FET）正电子发射断层扫描/磁共振成像进行胶质瘤复发与放射性坏死的鉴别诊断的潜力：一项前瞻性评估。
Neurol India. 2017 Mar-Apr;65(2):293-301. doi: 10.4103/neuroindia.NI_101_16.
5
Comparison of O-(2-F-Fluoroethyl)-L-Tyrosine Positron Emission Tomography and Perfusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Patients with Progressive and Recurrent Glioma: A Hybrid Positron Emission Tomography/Magnetic Resonance Study.O-(2-氟乙基)-L-酪氨酸正电子发射断层扫描与灌注加权磁共振成像在进展性和复发性胶质瘤患者诊断中的比较：一项正电子发射断层扫描/磁共振混合研究
World Neurosurg. 2018 May;113:e727-e737. doi: 10.1016/j.wneu.2018.02.139. Epub 2018 Mar 3.
6
Multimodal imaging in cerebral gliomas and its neuropathological correlation.脑胶质瘤的多模态成像及其神经病理学相关性
Eur J Radiol. 2014 May;83(5):829-34. doi: 10.1016/j.ejrad.2014.02.006. Epub 2014 Feb 15.
7
Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.基于氟乙基酪氨酸 PET 和 MRI 的体素分析在抗血管生成治疗期间评估复发性脑胶质瘤。
AJR Am J Roentgenol. 2018 Dec;211(6):1342-1347. doi: 10.2214/AJR.18.19988. Epub 2018 Oct 17.
8
Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy.分析适形放疗治疗脑胶质瘤患者时 FET-PET 成像在靶区勾画中的作用。
Radiother Oncol. 2013 Dec;109(3):487-92. doi: 10.1016/j.radonc.2013.06.043. Epub 2013 Aug 13.
9
Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma.弥散加权 MRI 和 ADC 与 FET-PET 和 GdT1w-MRI 对比在复发性胶质母细胞瘤再放疗中的大体肿瘤体积（GTV）勾画。
Radiother Oncol. 2019 Jan;130:121-131. doi: 10.1016/j.radonc.2018.08.019. Epub 2018 Sep 12.
10
Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors.18F-FET PET 与灌注加权磁共振成像的比较：脑肿瘤患者的 PET/MR 成像杂交研究。
J Nucl Med. 2014 Apr;55(4):540-5. doi: 10.2967/jnumed.113.129007. Epub 2014 Feb 27.
引用本文的文献
1
A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy.美国食品药品监督管理局（FDA）批准的用于脑肿瘤治疗的多靶点血管生成药物综述。
Int J Mol Sci. 2025 Feb 28;26(5):2192. doi: 10.3390/ijms26052192.
2
Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.瑞戈非尼与胶质母细胞瘤：文献综述包括临床前研究、分子机制和临床疗效。
Expert Rev Mol Med. 2024 Apr 2;26:e5. doi: 10.1017/erm.2024.8.
3
Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group.脑肿瘤患者正电子发射断层扫描和高级磁共振成像的挑战、局限性和陷阱：PET/RANO 小组的报告。
Neuro Oncol. 2024 Jul 5;26(7):1181-1194. doi: 10.1093/neuonc/noae049.
本文引用的文献
1
PET/MR in recurrent glioblastoma patients treated with regorafenib: [F]FET and DWI-ADC for response assessment and survival prediction.替莫唑胺联合放疗同步与序贯卡培他滨治疗新诊断胶质母细胞瘤的多中心随机对照 III 期临床研究
Br J Radiol. 2022 Jan 1;95(1129):20211018. doi: 10.1259/bjr.20211018. Epub 2021 Nov 23.
2
Modification of MRI pattern of high-grade glioma pseudoprogression in regorafenib therapy.在regorafenib 治疗中高级别胶质瘤假性进展的 MRI 模式改变。
J Med Imaging Radiat Oncol. 2022 Apr;66(3):414-418. doi: 10.1111/1754-9485.13267. Epub 2021 Jun 24.
3
Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI.瑞戈非尼治疗恶性胶质瘤后的影像学表现：FET PET为解剖学MRI增添了有价值的信息。
Neurooncol Adv. 2019 Oct 20;1(1):vdz038. doi: 10.1093/noajnl/vdz038. eCollection 2019 May-Dec.
4
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.雷戈非尼对比洛莫司汀治疗复发性胶质母细胞瘤患者（REGOMA）：一项多中心、开放标签、随机、对照、2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):110-119. doi: 10.1016/S1470-2045(18)30675-2. Epub 2018 Dec 3.
5
Advances in neuro-oncology imaging.神经肿瘤影像学进展。
Nat Rev Neurol. 2017 May;13(5):279-289. doi: 10.1038/nrneurol.2017.44. Epub 2017 Apr 7.
6
Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.贝伐单抗诱导的进行性扩散受限与复发性胶质母细胞瘤患者中被存活肿瘤包围的凝固性坏死及总生存期缩短有关。
AJNR Am J Neuroradiol. 2016 Dec;37(12):2201-2208. doi: 10.3174/ajnr.A4898. Epub 2016 Aug 4.
7
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.神经肿瘤学中的免疫治疗反应评估：RANO工作组报告
Lancet Oncol. 2015 Nov;16(15):e534-e542. doi: 10.1016/S1470-2045(15)00088-1.
8
Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.贝伐珠单抗治疗的恶性胶质瘤中持续存在弥散受限病灶与改善生存相关，与匹配对照相比。
AJNR Am J Neuroradiol. 2012 Oct;33(9):1763-70. doi: 10.3174/ajnr.A3053. Epub 2012 Apr 26.
9
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.高级别胶质瘤更新后的反应评估标准：神经肿瘤学工作组的反应评估。
J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.
Zotero 插件